NIH conference. Somatostatin and somatostatin analogue (SMS 201-995) in treatment of hormone-secreting tumors of the pituitary and gastrointestinal tract and non-neoplastic diseases of the gut.
about
Somatostatin analogues for treatment of enterocutaneous fistulaCirculating biomarkers of response to sunitinib in gastroenteropancreatic neuroendocrine tumors: current data and clinical outlookA prospective examination of octreotide-induced gall-bladder changes in acromegalySomatostatin analogue (octreotide) inhibits bile duct epithelial cell proliferation and fibrosis after extrahepatic biliary obstructionSomatostatin and octreotide in the prevention of postoperative pancreatic complications and the treatment of enterocutaneous pancreatic fistulas: a systematic review of randomized controlled trials.Malignant insulinoma: spectrum of unusual clinical features.Insulinoma and anaesthetic implicationsSomatostatin binding in human gastrointestinal tissues: effect of cations and somatostatin analogues.Correlation between gall bladder fasting volume and postprandial emptying in patients with gall stones and healthy controls.Treatment of the carcinoid syndrome with the longacting somatostatin analogue lanreotide: a prospective study in 39 patientsSomatostatin analogs and radiopeptides in cancer therapy.Somatostatin analogues in the treatment of endocrine tumors of the gastrointestinal tract.Somatostatin and growth hormone regulation in cancer.Failure of somatostatin analogue to control Cushing's syndrome in two cases of ACTH-producing carcinoid tumours.The effect of a somatostatin analogue on the release of hormones from human midgut carcinoid tumour cells.Experimental and clinical studies with somatostatin analogue octreotide in small cell lung cancerComparative studies on the expression of somatostatin receptor subtypes, outcome of octreotide scintigraphy and response to octreotide treatment in patients with carcinoid tumours.Neuropeptide growth factors.Therapeutic strategies in the management of endocrine GEP tumours.Shrinkage of thyrotrophin secreting pituitary adenoma treated with octreotideTSH-Secreting Pituitary Adenoma: Current Management and Review.Rare functioning pancreatic endocrine tumors.Hepatopulmonary syndrome: an evolving perspective in the era of liver transplantation.Neuroendocrine metastases of the liver.The long-acting somatostatin analogue octreotide alleviates symptoms by reducing posttranslational conversion of prepro-glucagon to glucagon in a patient with malignant glucagonoma, but does not prevent tumor growth.Palliative treatment of neuroendocrine tumors.Consensus statement: octreotide dose titration in secretory diarrhea. Diarrhea Management Consensus Development Panel.Intraocular transplantation and primary cell cultures as experimental models for the study of human carcinoid disease.Hepatic arterial chemoembolization in patients with liver metastases of endocrine tumors. A prospective phase II study in 24 patients.Octreotide in the treatment of refractory diarrhoea and intestinal fistulaeOccult retroperitoneal carcinoid tumor with flushing and solitary lung metastasis.Effects of octreotide on biliary lipid composition and occurrence of cholesterol crystals in patients with acromegaly. A prospective study.The paradoxical effects of somatostatin on the bioactivity and production of cytotoxins derived from human peripheral blood mononuclear cells.Persistent or recurrent acromegaly. Long-term endocrinologic efficacy and neurologic safety of postsurgical radiation therapy.Effect of octreotide on fluid absorption and secretion by the normal human jejunum and ileum in vivo.Somatostatin in gastroenterology.Vipoma: effective treatment with octreotide in the oldest old.Inhibitory effect of the somatostatin analog octreotide on rat pituitary tumor cell (GH3) proliferation in vitro.Prospective study of the antitumor efficacy of long-term octreotide treatment in patients with progressive metastatic gastrinoma.Sandostatin LAR (long-acting octreotide acetate) for malignant carcinoid syndrome: a 3-year experience.
P2860
Q24198107-2BA05692-BF08-4DEF-AE1B-78470CF0A366Q26823035-EB3D246E-17FD-4064-9055-4C2F1D753F6BQ28319481-E3F91A10-229D-4809-B77F-76CABED30D37Q28378390-2356B54C-D8F8-4B34-BFB1-CE504713889EQ31893888-A81C12DF-56A4-4AFF-A8E7-D8D09FB8DD19Q34061054-5AAFA361-8AFB-431C-9B2A-B4C3F53B3D0BQ34304877-281A1C46-79E9-472A-A3DC-B2D5BD33AC6CQ34378050-B62F24A8-A621-4F8A-B556-4C8B2FE1C63BQ34378172-08547AAB-1EB0-4DA2-9066-DEE15B9CD4C2Q34410241-2056DBD5-F336-41F6-8816-383D008FDCC7Q34972896-93EC2F4B-3A09-42CD-BEE9-BA8714129371Q35020349-B5214E1F-E0CF-40A4-BD7F-6E1E9A305370Q35251198-CD8E7B01-265B-49DD-B85F-4AE6AB375007Q35479055-575FD2E9-5399-4006-834E-1F28526F242EQ35992853-921EB28A-8B70-403C-887C-156A34B86804Q35993786-A7307342-6B31-4E3F-8580-B36CE9764FEBQ36291710-138D848C-BA77-42F9-AA54-B64CCF6E571AQ36535839-8401340B-2478-464F-A21C-B05CCF4B9CE5Q36615663-7ABDA72E-5508-420C-9953-E0C740364AF5Q36681668-48FA932B-A6A0-4FD9-918F-F548B8087151Q36684950-12F35E49-AC7C-43D2-AC2F-4A368F77E1A2Q36741124-13011F9E-27C6-461E-B9B2-9BE75B901D34Q38138044-80BD3343-0B81-480D-8313-3E85703688E3Q39478794-55B143AB-554E-402A-94D2-CFE2515F8996Q39487999-2A3AD549-BC3A-4FDD-AEDA-21A340E685F6Q40384226-0D4AFEA5-C93D-4E01-88EF-F969D1B91FD1Q40456458-444FBEB4-8D3F-407D-B67E-C939C2678FB9Q40642508-707DECBD-E967-4443-B35F-7C470D77E045Q40718905-9425284E-C6BA-43E9-A4F9-FECD9907076FQ40764385-A33528A9-0187-41E0-BBF0-F331133144AAQ42148122-E91C8B7B-3295-4E60-8A52-4F8A17F5F2DBQ42282386-82E77D69-DFC2-416E-B10C-2641CAD73F81Q42372629-FB4D52E9-11F5-4E24-A444-48B115231D70Q42467886-5F857372-5B01-46C2-AA0F-557B6CC1E52CQ42519665-CC32BB55-0856-4F64-A1FF-3B25A5CE7082Q42582957-D992EF43-DA9E-4846-8391-7178AAB12204Q43603863-3F6B7840-60E2-430B-BE56-02B2CCC725E7Q43856450-6F86AC26-AF3E-4CDB-AD9A-9735AC168399Q43921041-86DA18DB-BA2D-4C7B-B304-AA4A50CADD73Q44299626-9180E89E-4A1A-425C-A22F-FAAF70083CEE
P2860
NIH conference. Somatostatin and somatostatin analogue (SMS 201-995) in treatment of hormone-secreting tumors of the pituitary and gastrointestinal tract and non-neoplastic diseases of the gut.
description
1989 nî lūn-bûn
@nan
1989年の論文
@ja
1989年論文
@yue
1989年論文
@zh-hant
1989年論文
@zh-hk
1989年論文
@zh-mo
1989年論文
@zh-tw
1989年论文
@wuu
1989年论文
@zh
1989年论文
@zh-cn
name
NIH conference. Somatostatin a ...... eoplastic diseases of the gut.
@en
type
label
NIH conference. Somatostatin a ...... eoplastic diseases of the gut.
@en
prefLabel
NIH conference. Somatostatin a ...... eoplastic diseases of the gut.
@en
P2093
P1476
NIH conference. Somatostatin a ...... eoplastic diseases of the gut.
@en
P2093
P356
10.7326/0003-4819-110-1-35
P407
P577
1989-01-01T00:00:00Z